Coherus Oncology Inc (CHRS)

SG&A Expenses

$90.50M

TTM · Period ending: · USD

CHRS logo

CHRS SG&A Expenses

Latest reported$90.50M
CHRS TTM SG&A Expenses ($7.47M → $90.50M)
High-resolution chart · PNG

CHRS sg&a expenses history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Coherus Oncology Inc SG&A Expenses — Trailing twelve months (TTM) (USD)
Period endingSG&A Expenses (USD)
90,498,000
95,583,000
98,504,000
116,192,000
128,105,000
137,231,000
151,438,000
159,635,000
173,115,000
183,094,000
192,015,000
196,142,000
192,749,000
198,881,000
198,481,000
194,912,000
190,006,000
179,075,000
169,713,000
157,354,000
149,413,000
143,120,000
139,079,000
137,456,000
137,300,000
139,704,000
137,037,000
134,807,000
128,348,000
110,283,000
94,177,000
75,315,000
63,935,000
69,077,000
71,303,000
71,619,000
71,275,000
59,002,000
51,597,000
47,275,000
43,796,000
41,353,000
36,046,000
31,260,000
25,073,000
20,234,000
17,564,000
13,875,000
12,251,000
9,597,000
7,465,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.